Molecular Partners AG MOLN.SW · Stock Open Molecular Partners AG in new tab
Molecular Partners AG Analysis (MOLN.SW)
Is Molecular Partners AG a good investment? Molecular Partners AG (MOLN.SW) is currently trading at 3.40 CHF. Market analysts have a consensus price target of 9.00 CHF. This suggests a potential upside from current levels.
Earnings Schedule: Molecular Partners AG is expected to release its next earnings report on Aug. 25, 2026. The market consensus estimate for Forward EPS is 0.23.
Investor FAQ
Does Molecular Partners AG pay a dividend?
No, it does not currently pay a dividend.
What asset class is Molecular Partners AG?
Molecular Partners AG is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Aug. 25, 2026. The company currently has a trailing EPS of -1.55.
Company Profile
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Community Discussion